AstraZeneca’s Cancer Drug Trial Disappoints, Sending Shares Lower

Thursday, July 27, 2017 - 06:02 in Health & Medicine

The treatment had been expected to be a crucial driver of growth for the company as it faces more competition from generic pharmaceuticals.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net